Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

BACKGROUND: Glucocorticoids (GCS) remain one of the mainstay treatments in the management of ulcerative colitis (UC) but up to a third of patients will ultimately fail to respond and progress to a more severe and difficult to manage disease state. Previous clinical studies suggest that the Toll-Like...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuznetsov, Nikolai V, Zargari, Arezou, Gielen, Alexander W, von Stein, Oliver D, Musch, Eugen, Befrits, Ragnar, Lofberg, Robert, von Stein, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005617/
https://www.ncbi.nlm.nih.gov/pubmed/24758565
http://dx.doi.org/10.1186/1471-230X-14-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005617/
https://www.ncbi.nlm.nih.gov/pubmed/24758565
http://dx.doi.org/10.1186/1471-230X-14-79

Ejemplares similares